{"id":37496,"date":"2025-12-03T01:09:09","date_gmt":"2025-12-03T01:09:09","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=37496"},"modified":"2025-12-03T01:09:44","modified_gmt":"2025-12-03T01:09:44","slug":"xeltis-raises-e50-million-to-advance-commercialization-of-axess-vascular-access-conduit","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/xeltis-raises-e50-million-to-advance-commercialization-of-axess-vascular-access-conduit\/","title":{"rendered":"Xeltis Raises \u20ac50 Million to Advance Commercialization of aXess Vascular Access Conduit"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Netherlands-based <a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/xeltis\/\" target=\"_blank\" rel=\"noreferrer noopener\">Xeltis<\/a> has obtained nearly \u20ac50 million in new financing to accelerate commercialization of aXess, its vascular access conduit designed for patients undergoing hemodialysis. The funding includes up to \u20ac37.5 million from the European Investment Bank (EIB), supported by the European Commission\u2019s InvestEU program, and \u20ac10 million from existing shareholders such as <a href=\"https:\/\/g-medtech.com\/directory\/listings\/eqt\/\" target=\"_blank\" rel=\"noreferrer noopener\">EQT Life Sciences<\/a> and Invest-NL. The company plans to use the capital to scale manufacturing, expand its workforce, and support development across its broader implant portfolio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The investment follows strong results from Xeltis\u2019 EU pivotal trial, which assessed the patency, safety, and performance of aXess in adults with end-stage renal disease requiring vascular access. The device met all primary endpoints and demonstrated sustained patency along with reduced infections and fewer interventions compared with current standards of care. A US pivotal trial is progressing, with interim data expected in 2026 ahead of a planned pre-market approval submission.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With this new funding, Xeltis expects to move aXess closer to both European market approval and US pre-market approval in 2026. \u201cWe are deeply grateful for the continued support of the EIB and our existing investors and proud of the confidence they have shown in Xeltis at this key moment for the company,\u201d said CEO Eliane Schutte. She noted that the company is preparing to expand its facilities and hire additional staff to bring aXess to market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Robert de Groot, Vice President at the EIB, said the bank is backing the project because \u201cXeltis is at the cutting-edge of their field, directly contributing to improved outcomes for dialysis and cardiovascular patients.\u201d He emphasized that the \u20ac37.5 million venture debt commitment reflects Europe\u2019s aim to strengthen its MedTech leadership.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Xeltis will also channel part of the financing toward its pipeline of implants developed using its Endogenous Tissue Restoration platform. This includes Xabg, a coronary artery bypass conduit that recently delivered strong 24-month follow-up results, and several other early-stage programs targeting additional cardiovascular conditions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xeltis has secured close to \u20ac50 million from the European Investment Bank and existing investors to expand production, advance regulatory milestones, and prepare its aXess vascular access conduit for expected EU and US approvals in 2026.<\/p>\n","protected":false},"author":2,"featured_media":37497,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[488,680,6,10,671],"tags":[594],"class_list":["post-37496","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","category-cardiovascular","category-europe","category-strategic-development","category-top-news","tag-financing"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/37496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/comments?post=37496"}],"version-history":[{"count":2,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/37496\/revisions"}],"predecessor-version":[{"id":37499,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/37496\/revisions\/37499"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media\/37497"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media?parent=37496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/categories?post=37496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/tags?post=37496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}